The Pharma Letter12h
Positive Phase III ACTIVATE-Kids study of Agios’ mitapivat
USA-based Agios Pharmaceuticals has announced that the ACTIVATE-Kids Phase III study of mitapivat in children aged 1 to <18 ...
Monthly Prescribing Reference17d
Novel Therapy for Pyruvate Dehydrogenase Complex Deficiency Gets Priority Review
SL1009 is expected to increase energy production by inhibiting pyruvate dehydrogenase kinase and stimulating residual pyruvate dehydrogenase complex activity. The NDA is supported by data from a ...
Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint
ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused –– ...